Repertoire Immune Medicines Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 155

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $189M

  • Investors
  • 6

Repertoire Immune Medicines General Information

Description

Operator of a clinical-stage biotechnology company intended to unlock and direct the human immune system to prevent or treat cancer. The company offers repertoire of T cell receptor (TCR)-antigen codes that drive health and disease and helps in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines, enabling clinicians to prevent or treat cancer, autoimmune disorders, infectious diseases, and other serious diseases among patients.

Contact Information

Formerly Known As
Torque, Torque Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
  • One Kendall Square
  • Cambridge, MA 02139
  • United States

Repertoire Immune Medicines Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Repertoire Immune Medicines Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 13-Apr-2021 $189M 00000 Completed Generating Revenue
3. Early Stage VC 25-Mar-2020 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 15-Jul-2019 $38.3M $84.3M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 18-Apr-2018 $46M $46M 0000 Completed Generating Revenue
To view Repertoire Immune Medicines’s complete valuation and funding history, request access »

Repertoire Immune Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00 00 00 00.000
Series A1 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 15,776,666 $0.000100 $1 $1 1x $1 23.28%
To view Repertoire Immune Medicines’s complete cap table history, request access »

Repertoire Immune Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biotechnology company intended to unlock and direct the human immune system to prevent or t
Biotechnology
Cambridge, MA
155 As of 2022
00000
00000000000 00000

000000

labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris ni
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000 0

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna a
0000000000000
Santa Monica, CA
000 As of 0000
00000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Repertoire Immune Medicines Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
00000000 000 Formerly VC-backed Somerville, MA 000 00000 000000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

Repertoire Immune Medicines Patents

Repertoire Immune Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220033460-A1 Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19 Pending 30-Jul-2020 000000000
CA-3176448-A1 Barcodable exchangeable peptide-mhc multimer libraries Pending 31-Mar-2020 000000000000
AU-2021248941-A1 Barcodable exchangeable peptide-mhc multimer libraries Pending 31-Mar-2020 000000000000
EP-4084802-A1 Compositions of hydrogels and methods of use thereof Pending 03-Jan-2020 0000000000
US-20220195071-A1 Immunotherapeutic compositions and use thereof Pending 29-Mar-2019 C07K17/04
To view Repertoire Immune Medicines’s complete patent history, request access »

Repertoire Immune Medicines Executive Team (18)

Name Title Board Seat Contact Info
Anne Walker Executive Vice President & Chief Financial Officer
Lucia Celona Chief Human Resources Officer & Executive Vice President
John Delyani Ph.D Chief Business Officer
Ewen Cameron Ph.D Co-Founder
Thomas Andresen Ph.D Co-Founder
You’re viewing 5 of 18 executive team members. Get the full list »

Repertoire Immune Medicines Board Members (11)

Name Representing Role Since
Douglas Cole MD Flagship Pioneering Chairman 000 0000
Douglas Lauffenburger Ph.D Self Board Member 000 0000
John Cox Repertoire Immune Medicines Board Member & Advisor 000 0000
John Mendlein Ph.D Flagship Pioneering Board Member 000 0000
Lynne Parshall ESQ Repertoire Immune Medicines Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Repertoire Immune Medicines Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Repertoire Immune Medicines Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alaska Permanent Fund Sovereign Wealth Fund Minority 000 0000 000000 0
Public Sector Pension Investment Board Asset Manager Minority 000 0000 000000 0
SoftBank Investment Advisers Growth/Expansion Minority 000 0000 000000 0
The Invus Group PE/Buyout Minority 000 0000 000000 0
T1D Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »